Sustained Release Oral Formulation for Treatment of Parkinson's Disease
University of Minnesota
Summary
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Normal healthy * Are 18-65 years of age * Are not currently taking medications regularly * Able to fast 6 hours (water allowed) Exclusion Criteria: * Pregnancy * Inability to fast
Interventions
- Druglevodopa/carbidopa oral formulation A
Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
- Druglevodopa/carbidopa oral formulation B
Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
Location
- University of MinnesotaMinneapolis, Minnesota